GAO Denies Bode Cellmark Protest of SNA International ICE Rapid DNA IDIQ, Affirming SBIR Phase III Noncompetitive Sole-Source Authority

On December 3, 2025, the Government Accountability Office denied the protest filed by Bode Cellmark Forensics Inc. (d/b/a Bode Technology) against ICE’s noncompetitive award of contract 70CMSD25D00000001 to SNA International LLC for rapid DNA testing services. The denial (GAO Case B-423754, B-423754.2) affirmed ICE’s authority to award an operational enforcement contract to SNA without competition under the SBIR Phase III sole-source mechanism, lifted the stop-work order that had halted performance since May 27, and confirmed the legal scaffolding that routes around the open-recompete checkpoint in the DHS biometric surveillance pipeline.

Protest Timeline

• 2025-05-14: ICE awards base IDIQ 70CMSD25D00000001 to SNA International (one offer received; noncompetitive SBIR Phase III).
• 2025-05-23: Bode Cellmark Forensics files protest with GAO challenging the award.
• 2025-05-27: ICE issues stop-work order on contract performance in response to protest.
• 2025-11-24: Task order 70CMSD25FR0000034 modified to extend period of performance to 2026-11-06 (anticipating protest resolution).
• 2025-12-03: GAO denies protest (B-423754, B-423754.2). Contract reinstated; stop-work lifted.

The Protestor: Bode Cellmark Forensics

Bode Cellmark Forensics Inc., doing business as Bode Technology, is a Lorton, Virginia forensic DNA laboratory with directly relevant capabilities in rapid DNA testing and forensic genomics. Bode is a competitor in the same product space SNA serves — forensic DNA analysis for government clients — making it a natural unsuccessful offeror on an open-competition contract it was legally precluded from bidding on via the SBIR Phase III sole-source mechanism.

Bode had previously been awarded separate ICE contracts in the rapid DNA space (GAO docket shows a prior Bode protest at B-423560.1). This was not a vexatious or unrelated protest; it was a direct market competitor challenging the procurement instrument that locked it out.

Protest Grounds

Bode Cellmark raised two principal grounds:

Ground 1 — Improper noncompetitive award: Bode contended that ICE improperly awarded the IDIQ as a noncompetitive SBIR Phase III award. The core challenge was that the SBIR Phase III mechanism — which authorizes sole-source awards when work “derives from, extends, or completes” prior SBIR research — was being misapplied to justify locking out competition on what was effectively an operational procurement rather than a continuation of R&D.

Ground 2 — Commercial equipment content exceeds SBIR scope: Bode argued that “most of the contract will be for commercially available testing equipment,” contending that because the majority of contract dollar value would flow to commercial-off-the-shelf rapid DNA instruments rather than to the software and analytical services SNA had developed through SBIR, the SBIR sole-source authority was exceeded. The implicit argument: if you strip out the commercial gear, what remains that is genuinely SBIR-derived?

GAO Reasoning for Denial

GAO denied both grounds, with the following holdings:

On the “derives from” standard: GAO found that ICE’s requirement for implementing a rapid DNA testing program — including DNAConnect software, the DNA Reach-Back Support System (RBSS) architecture, the support center, and accredited laboratory operations — “derives from, extends, or completes” SNA’s Phase I and Phase II SBIR work. The agency had established in its record that “the proposed rapid DNA solution derived from and extended the research, architecture, and technical design developed under SNA’s phase I and II contracts.” GAO credited this agency determination. The “derives from” test, as applied, does not require that all contract elements be novel SBIR outputs; it requires that the overall requirement be substantially connected to prior SBIR work.

On the commercial equipment argument (the “price test” rejection): GAO explicitly ruled that “Nothing in the SBIR authority establishes a ‘price test.’” The percentage of total contract value attributable to commercially available equipment does not determine whether SBIR Phase III authority applies. GAO’s holding: an agency may use SBIR Phase III sole-source authority to procure systems where some aspects derive from prior SBIR efforts and other aspects are commercially available components — so long as the overall requirement is SBIR-connected. This ruling effectively forecloses a major category of protest ground against SBIR Phase III sole-source awards going forward.

The structural effect of the holding: Any competitor seeking to challenge an SBIR Phase III sole-source award on the grounds that commercial components constitute the bulk of contract value will now face the B-423754 precedent as an obstacle. The GAO has closed off the “price test” avenue, leaving competitors with only the narrower “derives from” factual dispute — which agencies control through the administrative record they build.

What the Denial Means Structurally

The B-423754 denial is not merely a contract dispute outcome. It is a documented instance of legal architecture consolidation for the DHS SBIR → operational biometric procurement pipeline:

Noncompetitive conversion validated: ICE’s use of SBIR Phase III to award a $25M operational DNA collection contract without open competition survived the one legal challenge mechanism available — GAO protest. The accountability pathway (protest → GAO review → stop-work → potential corrective action) ran its full course and affirmed the award.

The route-around is documented and defensible: The SBIR Phase III mechanism is the legal instrument that bypasses the open-recompete checkpoint. B-423754 confirms this bypass is lawful under the statute as written, even when: (a) the awardee is a small company with an exclusive relationship to the government R&D program it now operationalizes, (b) a capable competitor exists and wants to bid, and (c) the majority of contract value may flow to commercial equipment rather than novel SBIR-derived technology. See: route-around-the-checkpoint-meta-mechanism-captured-x-administrative-bypass-architecture

Precedent for the defense-AI vertical: B-423754’s “no price test” holding applies beyond this specific contract. The same logic governs SBIR Phase III sole-source awards to Anduril, Palantir-adjacent companies, and other defense-AI vertical firms that have operationalized SBIR-funded R&D under noncompetitive operational contracts. The ruling strengthens the systemic SBIR Phase III fingerprint documented across the defense-AI vertical.

Comparison to Mercury Systems paradigm: In the Mercury Systems pattern (sbir-harvest-public-lp-both-sides-supply-chain-mercury-systems-paradigm), the SBIR-funded small company is acquired by a public aggregator that harvests the SBIR-derived data rights and Phase III contract rights. In SNA’s case, SNA remains the direct SBIR awardee and Phase III contractor — a simpler, single-firm version of the same route-around: the public R&D investment (Phase I + II SBIR funding) creates a private exclusive operational contract right (Phase III IDIQ), with the accountability bypass legally affirmed by GAO.

Post-Denial Contract Status

Following the December 3 denial, the stop-work order was lifted and SNA resumed performance under task order 70CMSD25FR0000034. The task order period runs through November 6, 2026. The base IDIQ ordering period extends to approximately 2027. Of the $25M ceiling, $6.2M has been obligated; $18.8M capacity remains for additional task orders. Bloomberg Law’s coverage of the denial quoted the contract’s total value as $28M — consistent with the $25M IDIQ ceiling plus potential option-year value beyond the base ordering period.

Needs-Entry Note

A SNA International organization profile does not exist in the cascade-research corpus. Candidate entry: /Users/markr/tcp-kb-internal/cascade-research/organizations/sna-international-llc.md — should document: SBIR history (Phase I 2019, Phase II 2020), DNAConnect product, Ballard Partners lobbying engagement (March 2025), ICE contract 70CMSD25D00000001, woman-owned small business status, Alexandria VA headquarters, and position in the multi-vendor biometric chain (SNA → ICE ERO → Palantir ICM).